SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells

Piao,Longzhen; Park,Jisoo; Li,Yuwen; Shin,Sanghee; Shin,Soyeon; Kong,Gyeyeong; Shrestha,Robin; Tran,Quangdon; Hur,Gang Min; Kim,Jeong-Lan; Park,Jongsun

doi:10.3892/ijmm.2014.1693

SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells

Authors:
- Longzhen Piao
- Jisoo Park
- Yuwen Li
- Sanghee Shin
- Soyeon Shin
- Gyeyeong Kong
- Robin Shrestha
- Quangdon Tran
- Gang Min Hur
- Jeong-Lan Kim
- Jongsun Park
View Affiliations

Affiliations: Department of Pharmacology, Metabolic Diseases and Cell Signaling Laboratory, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon 301-747, Republic of Korea, Department of Psychiatry, College of Medicine, Chungnam National University, Daejeon 301-131, Republic of Korea
Published online on: March 10, 2014 https://doi.org/10.3892/ijmm.2014.1693
Pages: 1364-1370

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Antipsychotic drugs are regularly used for the treatment of many types of psychiatric disorders. The administration of second-generation antipsychotics is often associated with weight gain and the development of diabetes mellitus; however, the molecular mechanisms underlying the effects of these drugs remain poorly understood. Leptin and insulin play key roles in the regulation of energy balance and glucose homeostasis, and resistance to the actions of these hormones can occur with obesity and inflammation, resulting in the pathogenesis of obesity and type 2 diabetes. In this study, the effects of risperidone on the insulin-induced protein kinase B (PKB) phosphorylation and leptin-stimulated signal transducer and activator of transcription 3 (STAT3) phosphorylation were investigated in the human SH-SY5Y neuroblastoma cell line. The treatment of these cells with risperidone induced the activation of extracellular signal-related kinase (ERK) by cellular cyclic adenosine 3-monophosphate (cAMP)-dependent protein kinase (also known as protein kinase A; PKA) and the mechanisms involved include the induction of suppressor of cytokine signaling 3 (SOCS3) and suppressor of cytokine signaling 6 (SOCS6) expression. The risperidone-induced ERK activation induced an upregulation of SOCS3 and SOCS6 mRNA expression levels. Taken together, these results suggest that risperidone modulates SOCS3 and SOCS6 expression through adenylate cyclase-mediated ERK activation, which, in turn, leads to an inhibition of insulin-induced PKB phosphorylation and leptin-stimulated STAT3 phosphorylation. Eventually, these effects result in excessive body weight gain due to the inhibition of both the leptin and insulin signaling pathways.

View Figures

View References

1	Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL and Muller DJ: Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 17:242–266. 2012. View Article : Google Scholar : PubMed/NCBI
2	Citrome L, Jaffe A, Levine J and Lindenmayer JP: Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry. 66:1512–1516. 2005. View Article : Google Scholar : PubMed/NCBI
3	Melkersson KI, Dahl ML and Hulting AL: Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl). 175:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
4	Scheen AJ and De Hert MA: Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 33:169–175. 2007. View Article : Google Scholar : PubMed/NCBI
5	Grace AA: Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev. 31:330–341. 2000. View Article : Google Scholar : PubMed/NCBI
6	Narendran R, Slifstein M, Guillin O, et al: Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse. 60:485–495. 2006.
7	Masi G, Cosenza A, Mucci M and Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 40:1206–1214. 2001. View Article : Google Scholar : PubMed/NCBI
8	Nasrallah H: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 28(Suppl 1): 83–96. 2003. View Article : Google Scholar
9	Claus A, Bollen J, De Cuyper H, et al: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 85:295–305. 1992. View Article : Google Scholar : PubMed/NCBI
10	Owens DG: Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry. 55:29–35. 1994.PubMed/NCBI
11	Morton GJ: Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol. 583:437–443. 2007. View Article : Google Scholar : PubMed/NCBI
12	Niswender KD, Baskin DG and Schwartz MW: Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab. 15:362–369. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hemmings BA and Restuccia DF: PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI
14	Coppari R and Bjorbaek C: Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov. 11:692–708. 2012. View Article : Google Scholar : PubMed/NCBI
15	Obici S, Feng Z, Morgan K, Stein D, Karkanias G and Rossetti L: Central administration of oleic acid inhibits glucose production and food intake. Diabetes. 51:271–275. 2002. View Article : Google Scholar : PubMed/NCBI
16	Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS and Myers MG Jr: Regulation of Jak kinases by intracellular leptin receptor sequences. J Biol Chem. 277:41547–41555. 2002. View Article : Google Scholar : PubMed/NCBI
17	Myers MG Jr: Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res. 59:287–304. 2004. View Article : Google Scholar : PubMed/NCBI
18	White DW, Kuropatwinski KK, Devos R, Baumann H and Tartaglia LA: Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. J Biol Chem. 272:4065–4071. 1997. View Article : Google Scholar : PubMed/NCBI
19	Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA and Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature. 387:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
20	Yoshimura A, Nishinakamura H, Matsumura Y and Hanada T: Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 7:100–110. 2005. View Article : Google Scholar : PubMed/NCBI
21	Miyamoto S, Duncan GE, Marx CE and Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 10:79–104. 2005. View Article : Google Scholar : PubMed/NCBI
22	Friedman JM and Halaas JL: Leptin and the regulation of body weight in mammals. Nature. 395:763–770. 1998. View Article : Google Scholar : PubMed/NCBI
23	Spiegelman BM and Flier JS: Obesity and the regulation of energy balance. Cell. 104:531–543. 2001. View Article : Google Scholar : PubMed/NCBI
24	Nilsson CL and Eriksson E: Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors? J Neural Transm Gen Sect. 92:213–220. 1993. View Article : Google Scholar : PubMed/NCBI
25	Insel PA and Ostrom RS: Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol. 23:305–314. 2003. View Article : Google Scholar : PubMed/NCBI
26	Sands WA, Woolson HD, Milne GR, Rutherford C and Palmer TM: Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol Cell Biol. 26:6333–6346. 2006. View Article : Google Scholar
27	Banks AS, Li J, McKeag L, et al: Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest. 115:2462–2471. 2005. View Article : Google Scholar : PubMed/NCBI
28	Mooney RA, Senn J, Cameron S, et al: Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem. 276:25889–25893. 2001. View Article : Google Scholar : PubMed/NCBI
29	Senn JJ, Klover PJ, Nowak IA, et al: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 278:13740–13746. 2003. View Article : Google Scholar : PubMed/NCBI
30	Ueki K, Kondo T and Kahn CR: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 24:5434–5446. 2004. View Article : Google Scholar
31	Wojtal KA, Hoekstra D and van Ijzendoorn SC: cAMP-dependent protein kinase A and the dynamics of epithelial cell surface domains: moving membranes to keep in shape. Bioessays. 30:146–155. 2008. View Article : Google Scholar : PubMed/NCBI
32	Stork PJ and Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12:258–266. 2002. View Article : Google Scholar : PubMed/NCBI
33	Metzger BE, Buchanan TA, Coustan DR, et al: Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 30(Suppl 2): S251–S260. 2007. View Article : Google Scholar : PubMed/NCBI
34	Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353:1209–1223. 2005. View Article : Google Scholar : PubMed/NCBI
35	Tran PV, Hamilton SH, Kuntz AJ, et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 17:407–418. 1997. View Article : Google Scholar : PubMed/NCBI
36	Csernansky JG, Miller JP, McKeel D and Morris JC: Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 16:144–149. 2002. View Article : Google Scholar : PubMed/NCBI
37	Akam E and Strange PG: Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol. 67:2039–2045. 2004. View Article : Google Scholar : PubMed/NCBI
38	Seeman P, Schwarz J, Chen JF, et al: Psychosis pathways converge via D2high dopamine receptors. Synapse. 60:319–346. 2006. View Article : Google Scholar : PubMed/NCBI
39	Albert PR, Neve KA, Bunzow JR and Civelli O: Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion. J Biol Chem. 265:2098–2104. 1990.PubMed/NCBI
40	Yang BH, Son H, Kim SH, Nam JH, Choi JH and Lee JS: Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci. 58:262–267. 2004. View Article : Google Scholar : PubMed/NCBI
41	Howard JK and Flier JS: Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab. 17:365–371. 2006. View Article : Google Scholar : PubMed/NCBI
42	Bjorbak C, Lavery HJ, Bates SH, et al: SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem. 275:40649–40657. 2000. View Article : Google Scholar : PubMed/NCBI
43	Rui L, Yuan M, Frantz D, Shoelson S and White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 277:42394–42398. 2002. View Article : Google Scholar : PubMed/NCBI
44	Laroche-Joubert N, Marsy S, Michelet S, Imbert-Teboul M and Doucet A: Protein kinase A-independent activation of ERK and H,K-ATPase by cAMP in native kidney cells: role of Epac I. J Biol Chem. 277:18598–18604. 2002. View Article : Google Scholar : PubMed/NCBI
45	Yee WM and Worley PF: Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol. 17:921–933. 1997.PubMed/NCBI
46	Richards JS: New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. Mol Endocrinol. 15:209–218. 2001.